Cannabinoid Development Continues to Thrive as Medicinal Cannabis Operations Expand

Thursday, March 9, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

PALM BEACH, Florida, March 9, 2017 /PRNewswire/ --

As the Medicinal Cannabis Sector continues to explode behind increased

public and political support, the development of high quality cannabis extracts and Cannabinoids are helping to boost the industry to new heights. Cannabis stocks with recent market trading and developments include: Vinergy Resources Ltd. (OTC:VNNYF)(CSE:VIN.CN),
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), Cronos Group Inc. (TSX-V:MJN), THC Biomed Intl Ltd. (OTC: THCBF) (CSE: THC.CN) and Aurora Cannabis Inc. (OTC: ACBFF) (TSX-V: ACB.V).

Vinergy Resources Ltd.(OTCQB:VNNYF)(CSE:VIN) in conjunction with its proposed acquisition of MJ Biopharma (announced December 14, 2016) is pleased to announce it has appointed Mr.Facundo Bacardi to its Board of Directors effective immediately. Mr.Bacardi is a member of the family that owns and controls Bacardi Ltd., a worldwide liquor manufacturer and distributor. From 1979 to 1991, he was the head of Bacardi's manufacturing and distribution division for Nassau, Brazil, Trinidad and Central America. Since 1990, Mr.Bacardi has served as a Director of Suramericana de Inversiones, S.A., an investment company located in Panama. He is a founding shareholder of JSM Capital Holding Corp., a shareholder and Director of Global Arena Holdings, Inc., Mr.Bacardi is also on the Honorary Consul for the Bahamas in Panama. Read this and more news for Vinergy Resources at

"We are excited to have someone of Mr.Bacardi's calibre and pedigree, join our team. We look forward to working closely with him on our strategy to roll out products and technologies internationally," said Mr. Kent Deuters, CEO of MJ Biopharma. Mr.Bacardi, said: "I am happy to be joining the team at Vinergy to pursue business in the cannabis industry. Given my life-long experience in the spirits industry I see several areas in which I can add immediate value for the Company."

In other Cannabis/Medical Marijuana performances of note in the markets:

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) closed up on Wednesday at $21.11 represent over 5% for the trading day. Zynerba Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Zynerba will be present at the 29th Annual ROTH Conference in Orange County, CA, on March 13, 2017 at 1:00 pm PT (4:00 pm ET)

Cronos Group Inc. (PRMCF) (TSX-V: MJN) was one of the few Cannabis companies trading yesterday closing up on Wednesday. Cronos Group announced last week that it has re-filed Management's Discussion and Analysis of financial results for the three and nine months ended September 30, 2016 (the "MD&A") pursuant to a review by staff of the Ontario Securities Commission. Cronos Group is a geographically diversified and vertically-integrated cannabis company that operates two wholly-owned Licensed Producers ("LPs") regulated within Health Canada's Access to Cannabis for Medical Purposes Regulations (the "ACMPR") and holds a portfolio of minority investments in other Licensed Producers and ACMPR applicants.

THC Biomed Intl Ltd. (OTCQB: THCBF) (CSE:THC.CN) closed up on the CSE exchange on Wednesday at $0.79 trading over 400,000 shares by the market close. THC BioMed Intl focuses on the cultivation of medical marijuana in Canada. The company intends to research and develop technologies, products, and services related to medical marijuana. It would sell its products and services, including medical marijuana to other licensed producers, patients, and physicians under Marijuana for Medical Purposes.

Aurora Cannabis Inc. (OTCQB: ACBFF) (TSX-V: ACB.V) struggled a bit trading on Wednesday, closing down over 5% on the OTC exchange and down over 4% on the TSX-V exchange. Aurora Cannabis announced this week that its proposal (the "Proposal") to acquire Peloton Pharmaceuticals Inc. ("Peloton"), a late-stage ACMPR-applicant, out of bankruptcy protection was approved by Peloton's creditors at a recent meeting (the "Creditor Meeting"). Peloton is constructing a 40,000 square foot cannabis production facility in Pointe Claire, Quebec, which received a "ready to build" letter from Health Canada in 2014.

DISCLAIMER: (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies is a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated three thousand nine hundred dollars for news coverage of the current press release issued by Vinergy Resources Ltd. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.

Contact Information: Media Contact Phone: +1(561)325-8757




Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store